Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kunhiraman, B.
Right arrow Articles by Fonseca, V.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Avandamet

Biju Kunhiraman

William Itoua-Nganongo

Vivian Fonseca

Tulane University Health Sciences Center, 1430 Tulane Ave (SL 53), New Orleans, Louisiana 70112, USA, vfonseca{at}tulane.edu

Type 2 diabetes mellitus is characterised by multiple defects including decreased insulin mediated glucose disposal, higher endogenous glucose production mainly from liver and inadequate pancreatic secretion of insulin. Metformin and thiazolidinediones (TZDs) decrease insulin resistance by different mechanisms of action, and since both have the advantage of decreasing hyperglycaemia without increasing insulin secretion, they make an attractive option for combination. Metformin decreases hepatic glucose production and enhances peripheral glucose uptake while TZDs, by acting on peroxisome proliferator-activated receptor-gamma (PPAR{gamma}) receptors increase glucose uptake.

The combination has also been shown to improve glycaemic control, improve insulin sensitivity and improve beta-cell function. The availability of the two drugs in one pill has the potential to improve patientcompliance and decrease costs.

Key Words: combination therapy • type 2 diabetes • rosiglitazone • metformin.

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 4, 268-271 (2004)
DOI: 10.1177/14746514040040041001
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?